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Abstract
Background: Considerable evidence has shown that neuroinflammation and oxidative stress play an important role
in the pathophysiology of postoperative cognitive dysfunction (POCD) and other progressive neurodegenerative
disorders. Increasing evidence suggests that acetaminophen (APAP) has unappreciated antioxidant and anti-inflammatory
properties. However, the impact of APAP on the cognitive sequelae of inflammatory and oxidative stress is unknown.
The objective of this study is to explore whether APAP could have neuroprotective effects on lipopolysaccharide (LPS)-
induced cognitive impairment in mice.
Methods: A mouse model of LPS-induced cognitive impairment was established to evaluate the neuroprotective effects
of APAP against LPS-induced cognitive impairment. Adult C57BL/6 mice were treated with APAP half an hour prior to
intracerebroventricular microinjection of LPS and every day thereafter, until the end of the study period. The Morris water
maze was used to assess cognitive function from postinjection days 1 to 3. Animal behavioural tests as well as
pathological and biochemical assays were performed to evaluate LPS-induced hippocampal damage and the
neuroprotective effect of APAP.
Results: Mice treated with LPS exhibited impaired performance in the Morris water maze without changing
spontaneous locomotor activity, which was ameliorated by treatment with APAP. APAP suppressed the accumulation
of pro-inflammatory cytokines and microglial activation induced by LPS in the hippocampus. In addition, APAP
increased SOD activity, reduced MDA levels, modulated glycogen synthase kinase 3β (GSK3β) activity and elevated
brain-derived neurotrophic factor (BDNF) expression in the hippocampus. Moreover, APAP significantly decreased the
Bax/Bcl-2 ratio and neuron apoptosis in the hippocampus of LPS-treated mice.
Conclusions: Our results suggest that APAP may possess a neuroprotective effect against LPS-induced cognitive
impairment and inflammatory and oxidative stress via mechanisms involving its antioxidant and anti-inflammatory
properties, as well as its ability to inhibit the mitochondrial permeability transition (MPT) pore and the subsequent
apoptotic pathway.
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Background
Postoperative cognitive dysfunction (POCD) is charac-
terized by a decline in cognitive function that occurs in
patients after anaesthesia and surgery when compared to
their preoperative cognitive status [1]. The decreased
cognitive functions include impairments in working
memory, long-term memory, information processing, at-
tention and cognitive flexibility [2, 3]. The incidence of
POCD indicates increased risk of mortality, decreased
quality of life, risk of early withdrawal from the work-
force and increased dependency [4]. There is emerging
evidence that neuroinflammation is implicated in the
pathophysiology of POCD and other progressive neuro-
degenerative disorders such as Alzheimer’s disease (AD),
Parkinson’s disease, amyotrophic lateral sclerosis (ALS)
and multiple sclerosis (MS) [5–7]. Evidence has also
shown that oxidative stress is harmful to cognitive func-
tion and is thought to contribute to the pathogenesis of
the above neurodegenerative diseases [8–10]. In fact,
neuroinflammation and oxidative stress exist simultan-
eously, and the interaction between oxygen free radicals
and inflammatory factors aggravates cognitive deficiency
[11, 12]. However, the exact pathogenesis underlying the
effect of neuroinflammation and oxidative stress on cog-
nitive function is still unclear.
Lipopolysaccharide (LPS) is a major bacterial TLR4
ligand that activates the innate immune response to in-
fections [13]. Intracerebroventricular administration of
LPS in mice produces cognitive impairment by expres-
sion of pro-inflammatory cytokines and neuronal death
via apoptosis [14–19], and oxidative stress induced by
LPS has been implicated in memory impairment [20].
This method can be effectively used as an animal model
for POCD [15, 19].
Acetaminophen (N-acetyl-4-aminophenol), also known
as APAP or paracetamol, is one of the most widely used
medications all over the world. APAP exhibits both anal-
gesic and antipyretic properties and has been widely
used as an active ingredient in many approved drugs.
Additionally, since the 1980s, APAP has become the first
drug of choice for the treatment of pain and fever in
children due to the high incidence of Reye’s syndrome
associated with aspirin [21]. According to the US Food
and Drug Administration (FDA), 479 drugs contain
APAP. As of August 2011, 235 out of the 479 APAP-
containing drugs have an active approval status, includ-
ing 214 prescription drug products owned by 31
companies and 21 over-the-counter (OTC) drug prod-
ucts produced by nine companies [22]. Given its wide
use and easy availability, scientists have recently begun
to examine APAP for off-label applications [22].
It has also been reported that APAP has neuroprotec-
tive effects. Maharaj et al. [23] reported that APAP
(0.25–1 mM) treatment ex vivo can inhibit cyanide-
induced superoxide anion generation and lipid peroxida-
tion in rat brain homogenates. Further animal study has
suggested that APAP (100 mg/kg/day, i.p.) can inhibit qui-
nolinic acid (QA)-induced lipid peroxidation, superoxide
anion generation, and cell damage in the rat hippocampus
[24]. Tripathy et al. [25, 26] showed that low-dose APAP
reduces inflammatory protein release from cultured brain
neuronal and endothelial cells exposed to oxidant stress
and increases expression of the anti-apoptotic protein Bcl-
2 in brain neurons. Naziroglu et al. [27] also reported that
APAP (5–100 mg/kg) can reduce brain and microsomal
lipid peroxidation, while it also increases brain vitamin E
levels and microsomal glutathione peroxidase (GSH-Px)
activity. In addition, APAP has been shown to protect
dopaminergic neurons from oxidative damage evoked by
acute exposure to 6-hydroxydopamine or excessive levels
of dopamine in vitro [28], suggesting a potential benefit
for PD. Finally, recent studies have shown that APAP
shows nootropic activity through increasing the escape la-
tency in the step through passive avoidance paradigm task
and decreasing acetyl cholinesterase activity in colchicine-
induced cognitive impairment (an animal model for AD)
in rats [29], suggesting a possible therapeutic effect of
APAP in AD.
Based on the above findings, we hypothesized that
during neuroinflammation, APAP might attenuate oxi-
dative stress and inflammatory cytokines in the hippo-
campus and thus improve cognitive impairment. To test
this hypothesis, we assessed the neuroprotective effects
of APAP against LPS-induced neuroinflammation and
oxidative damage in the present study. The results ob-
tained in this study may provide new insight into the




Adult male C57BL/6 (n = 80) mice aged 10–11 weeks
and weighing 21–23 g were purchased from Vital River
Laboratories Animal Technology Co. Ltd. (Beijing,
China. Permit Number: SCXK(JING) 2012-0001). All
mice were housed in groups of 3 to 5 per plastic cage
(24 × 36 × 24 cm) and given free access to standard food
and water in an air-conditioned room set at 24 ± 1 °C
with 50 ± 10% humidity, under a standard 12–12 light-
dark cycle (lights on 7 AM to 7 PM). The animals were
acclimatized for 7 days before the experiment and were
group-housed with the same cage mates throughout the
acclimation and testing periods. The procedures on ani-
mal experimentation were approved by the Animal Care
Committee of the Chinese People’s Liberation Army
General Hospital (Beijing, China). The maintenance and
handling of the mice were consistent with the guidelines
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of the National Institutes of Health, and adequate mea-
sures were taken to minimize animal discomfort.
Drug treatment
The mice were divided into four groups randomly (20 mice
per group): the control plus placebo group (CON group),
control plus APAP group (APAP group), LPS plus placebo
group (LPS group) and the LPS plus APAP group (A + L
group). The LPS-induced cognitive impairment mouse
model was performed according to a protocol previ-
ously described by our laboratory [19]. LPS was admin-
istered via the intracerebroventricular (i.c.v.) route.
Each mouse was anaesthetized with chloral hydrate
(400 mg/kg, i.p.). LPS (Sigma, St. Louis, MO, USA), dis-
solved in artificial cerebrospinal fluid (aCSF: 140 mM
NaCl, 3.0 mM KCl, 2.5 mM CaCl2, 1.0 mM MgCl2 and
1.2 mM Na2HPO4) with pH = 7.4 (2 μg in 2 μL), was in-
fused into the lateral ventricle using a mouse brain
stereotactic apparatus (Kopf Instruments, Tujunga, CA,
USA). The stereotactic coordinates from bregma were
derived according to Zhang [19]. The coordinates were
0.5 mm caudal to bregma, 1.0 mm right lateral to the
sagittal suture and 2.0 mm ventral of the dura. Using a
10-μL microsyringe, the injection speed was set at
0.667 μL/min and the needle was held in place for
2 min for proper dispersal of the drug from the tip fol-
lowing injection.
In mice in the CON group and APAP group, 2 μL of
aCSF was infused into the lateral ventricle. Mice in the
LPS group and A + L group were infused with LPS. Ani-
mals in the APAP group and A + L group received intra-
peritoneal injections of APAP (100 mg/kg/day) from day
0 starting 30 min prior to receiving the LPS injection,
until the end of the study period. Meanwhile, an equiva-
lent volume of vehicle (saline solution) for APAP was
given to the CON and LPS groups. The dosage of the
drug was chosen according to the results of our prelim-
inary study and is consistent with previous literature
sources where the agent was shown to have neuropro-
tective effects [23, 24].
Behavioural tests
Open field test (OFT)
To evaluate whether the lesioned performance by LPS
were attributable to changes in spontaneous locomotor
activity, anxiety and adaptivity to the Morris water maze
test, open field tests were performed 2 h before the
probe test for reference memory. A number of 10 mice
in each group (40 mice in total) were randomly selected
and subjected to behavioural test in this study. The open
field test was performed according to the previous study
[30]. The open field apparatus is a black woody box
(50 × 50 × 30 cm); the floor was divided into two concen-
tric square shape zones representing the close and far
distance to the central of the field. The test was per-
formed under a dark light of 50 lx. Mice were placed in
the centre of the open field and allowed a 5-min accli-
mation period. Their activities were recorded by an over-
head video camera. The total moving distance as well as
the moving duration in the open field was analysed
using animal behavioural tracking system (Smart, San
Diego Instruments, San Diego, CA, USA). The open
field apparatus was thoroughly cleaned with 5% ethyl
alcohol after the test of each mouse and allowed to dry
between tests.
Morris water maze (MWM)
The MWM test, which is a hippocampal-dependent test
of spatial learning, spatial memory and cognitive flexibil-
ity for rodents, was performed as described previously
with minor modifications [31]. The water maze was a
white circular tank made of polyvinyl chloride (118 cm
in diameter and 42 cm in height) and filled with white
non-toxic paint and water (23 ± 1 °C) to a depth of 28 cm.
The maze was placed in a room with several visual cues
for orientation in the maze. The maze was divided into
four quadrants: the first, second, third and fourth quad-
rants. An invisible platform (11 cm in diameter) was
placed 1 cm below the water surface in the first quadrant
(target quadrant). Spatial learning is assessed across re-
peated trials for 3 days (day −3 to day −1). Mice received
one training session consisting of eight trials per day for
continuous 3 days (day −3 (training session 1); day −2
(training session 2); day −1 (training session 3)). Mice
were released into the water facing the wall of the tank
from one of four separate quadrants and were allowed to
escape onto the hidden platform. The submerged platform
was always located in the first quadrant. A different start-
ing point was used on the eight trials. The mice were
trained to find the hidden platform and climb onto it
within 60 s. The animals were allowed to stay on the plat-
form for at least 10 s after each trial. When the mice failed
to reach the escape platform within 60 s, they were manu-
ally guided to the platform for 10 s by the experimenter.
After that, the mouse was removed to its cage and the
second animal was tested on trial 1. This rotation was
repeated until all animals completed trial 1. Subse-
quently, the process was repeated for subsequent trials
until eight trials completed per day for three consecu-
tive days. After each trial, animals were towel dried and
returned to their home cage under a heater for 10 min.
The animals’ movements were recorded with a video
camera attached to the ceiling.
On day 0, animals underwent LPS microinjection. On
postoperative day 1, probe tests for reference memory
were conducted on all the treated groups by removing
the hidden platform and releasing the mice in the third
quadrant (opposite to the first quadrant). Swimming
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speed, platform-site crossings, time travelled in the tar-
get quadrant, the percentage of distance travelled in the
target quadrant and distance around the platform were
recorded in a single 60-s trial. Reference memory was
determined by preference for the platform area.
On days 1, 2 and 3, working memory was tested, dur-
ing which both the platform and mice were randomly
placed in a novel position to assess working- or trial-
dependent learning and memory [31]. In this procedure,
the animal is given two trials per day. On each day, ani-
mals underwent the first training trial to ensure that all
mice learned the new platform location. After 15 s, the
second trial is the test trial or matching trial in which
each mouse was released from the same location as in
the first trial; if it recalled the first trial, the mice would
swim a shorter path to the platform in the second trial.
As the platform is moved daily, learning of platform pos-
ition from the previous day cannot be transferred to the
next day; hence, recall on each day during the second trial
is dependent on that day’s training trial and measures only
temporary or working memory. Measurement of data on
the second trial was conducted up to 60 s and the latency
for mice that could not reach the platform in the allotted
time was regarded as 60 s. Eventually, the escape latency
to the platform in the second trial was recorded as meas-
ure of temporary or working memory.
Tissue sampling
At 6, 24, 48 and 72 h after administration of LPS, the
mice were sacrificed by cervical decapitation under deep
pentobarbital sodium anesthesia. Transcardial perfusion
was performed with ice-cold standard phosphate-
buffered saline (PBS). The brains of six mice sacrificed at
24 h in each group were quickly removed and fixed in
4% paraformaldehyde for 48 h for histological analysis.
Then, the other brains were immediately removed and
washed in ice-cold saline. The hippocampus was dis-
sected and collected carefully in a sterile tube prior to
being snap-frozen in liquid nitrogen. The hippocampi
were stored at −80 °C until analysis. Hippocampi of mice
killed at 6 h were used for an enzyme-linked immuno-
sorbent assay (ELISA) for measuring inflammatory cy-
tokines. As previously recorded [32–35], LPS activates
microglia and induces pro-inflammatory protein se-
cretion within 6 h in the mouse hippocampus via the
NF-κB pathway. All other tests were carried out on
post-administration day 1, which corresponded to the
time point of the peak behavioural deficits.
ELISA
Concentrations of interleukin-1β (IL-1β), interleukin-6
(IL-6), and tumour necrosis factor α (TNF-α) were ex-
amined using an ELISA kit following the manufacturer’s
instructions (Biosource, Invitrogen, USA). Hippocampal
tissue was homogenized in RIPA lysis buffer (50 mmol/L
Tris–HCl, pH 6.8, 150 mmol/L NaCl, 5 mmol/L EDTA,
0.5% sodium deoxycholate, 0.5% NP-40) and supple-
mented with a cocktail containing protease and phos-
phatase inhibitors (Applygen, Beijing, China) on ice.
Supernatant protein concentrations were determined
after centrifugation at 12,000 rpm for 30 min with a
BCA Protein Assay reagent kit (Thermo Pierce, Rock-
ford, IL, USA). For each sample, 5 μL of extracted pro-
tein was used for detection. The procedure followed the
manufacturer’s instructions. The absorbance was read
on a spectrophotometer at a wavelength of 450 nm and
a reference wavelength of 650 nm. The concentrations
of IL-1β, IL-6 and TNF-α were calculated according to
the standard curve and presented as pg/mg protein.
Immunohistochemistry staining
A cerebral block containing the hippocampus and pre-
frontal cortex was fixed in 10% neutral-buffered formalin
overnight and then embedded in paraffin. Coronal 10-
μm sections were prepared and subjected to immunohis-
tochemistry staining. First, paraffin sections were
dewaxed and placed in EDTA buffer (pH 8.0) to repair
antigens. Second, sections were washed in 0.01% Triton
X-100 in phosphate-buffered saline (PBS-T) and blocked
with 3% bovine serum albumin (BSA) for 30 min at
room temperature. Then, they were incubated overnight
at 4 °C in the appropriate primary antibody, anti-Iba1
(1:100; WAKO). Next, the sections were incubated with
the appropriate secondary antibody, anti-rabbit IgG
(1:400; Jackson) for 2 h at room temperature. Glial re-
activity is characterized by an increase in the number of
cells and an alteration in cell morphology (rounding of
the cell bodies and thickening of processes), which leads
to an increase in Iba1 (ionized calcium-binding adaptor
molecule 1) labelling with increasing glial reactivity. An
increase in the integrated intensity/pixel area for Iba1
staining was interpreted to signify microglial reactivity.
The number of positively stained microglial cells per
view was counted using microscopy at ×200 magnifica-
tion. Images were captured using the Olympus BX5




MDA is a degraded oxidative lipid product from cell
membranes and is used as a reliable indicator of oxida-
tive stress [36]. The amount of MDA was measured by
the reaction of one molecule of MDA with two mole-
cules of TBA to yield a pink coloured chromogen. The
colour reaction was measured at 532 nm with a refer-
ence wavelength at 450 nm. The levels of MDA in the
hippocampi of mice were measured using commercial
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assay kits (Beyotime Biotechnology Institute, Nantong,
China) according to the manufacturer’s instructions.
Superoxide dismutase (SOD) activity
SOD is an endogenous scavenger of reactive oxygen spe-
cies (ROS) and is one of the major antioxidant enzyme
involved in protecting the nerve tissue from oxidative
stress. The activity of SOD was measured by the reaction
of NBT (nitro blue tetrazolium) with two molecules of
superoxide anion to yield a blue coloured chromogen, and
SOD has the ability to inhibit the superoxide anion free
radical O2
−. The colour reaction was measured at 560 nm
with a reference wavelength at 650 nm. The SOD activity
of tissue was also measured using commercial assay kits
(Beyotime Biotechnology Institute, Nantong, China) ac-
cording to the manufacturer’s instructions.
Western blot analysis
Hippocampal tissue was homogenized in RIPA lysis buf-
fer (50 mmol/L Tris–HCl, pH 6.8, 150 mmol/L NaCl,
5 mmol/L EDTA, 0.5% sodium deoxycholate, 0.5% NP-
40) plus protease inhibitor and phosphatase inhibitor
cocktail (Applygen, Beijing, China) on ice. Supernatant
protein concentrations were determined after centrifuga-
tion at 12,000 rpm for 30 min with a BCA Protein Assay
reagent kit (Thermo Pierce, Rockford, IL, USA). Equal
amount of the sample (40 μg of protein) was separated
on gradient sodium dodecyl sulphate–polyacrylamide
gels (SDS–PAGE) and transferred onto a polyvinylidene-
difluoride (PVDF) membrane, which was then blocked
with 5% skimmed milk solution. Afterward, the mem-
branes were incubated with primary antibodies overnight
at 4 °C. The primary antibodies used in this study were
rabbit anti-p-GSK-3β (Ser9) (1:1000; Cell Signaling
Technologies), rabbit anti-GSK-3β (1:1000; Cell Signal-
ing Technologies), rabbit anti-Bcl-2 (1:1000; Sigma-
Aldrich), mouse anti-Bax (1:50 Sigma-Aldrich), rabbit
anti-brain-derived neurotrophic factor (BDNF) IgG
(1:1000; Abcam) and mouse anti-β-actin IgG (1:3000;
Santa Cruz Biotechnology). After three washes with
TBST buffer, the membranes were incubated with goat
anti-mouse HRP or goat anti-rabbit HRP (1:3000; Santa
Cruz, Biotechnology) for 30 min each. The images were
digitized from the membrane, and the band intensity
was quantified using Gel-Pro Analyzer software, version
3.1 (Media Cybernetics, Bethesda, MD, USA).
Apoptosis assay
TUNEL assay was performed to analyse cell death ac-
cording to the manufacturer’s instructions using In Situ
Apoptosis Detection Kit, POD (Roche Applied Science,
Mannheim, Germany). The brain tissues including hip-
pocampal cornuammonis (CA) 1, CA3 and dentate
gyrus (DG) were harvested, immersed in 3% H2O2 and
washed with phosphate-buffered saline (PBS), incubated
with proteinase K solution (Life Technologies, Ambion)
at 37 °C for 20 min. Then, the sections were maintained
in TUNEL reaction mixture for 1 h at 37 °C, followed by
incubation in 50 μL converter POD for another 30 min
at 37 °C. After washing with PBS, the sections were in-
cubated with diaminobenzidine (DAB) substrate solution
for 10 min. Finally, images were taken using an Olympus
BX5 imaging system (Olympus America, Melville, NY,
USA) at ×100 and ×400 magnification. The number of
apoptotic neurons per view was counted using micros-
copy at ×400 magnification.
Statistical analysis
All data were analysed by an observer who was blind to
the experimental protocol. Statistical calculations were
performed using the statistical analysis software Graph-
Pad Prism, version 6.0 (GraphPad, San Diego, CA,
USA). Data were expressed as the mean ± standard error
(SE). Intergroup comparisons were conducted by two-way
ANOVA (LPS × APAP) followed by Tukey’s post hoc test
to determine significant differences between the experi-
mental group. For acquisition training (days −3 to −1) and
spatial working memory testing (days 1 to 3) of the
MWM, data were analysed using a two-way ANOVA
(treatment × trial time) with repeated measures (trial days)
followed by a Bonferroni post hoc test to analyse the dif-
ference in escape latency between each group. P values
<0.05 were considered statistically significant.
Results
Spontaneous locomotor activity was not changed 24 h
after LPS administration
To evaluate whether the changes in performance after
LPS administration were attributable to changes in
spontaneous locomotor activity, the open field test was
conducted [37]. No significant difference was observed
in locomotor performance (total moving distance and
moving duration) 24 h after LPS treatment between
the animals in the LPS, A + L, CON and APAP groups
(Fig. 1a, b), suggesting that the impaired performance
in the LPS group was not a result of reduced loco-
motor ability.
APAP attenuated LPS administration-induced learning
and memory impairment
Previous work in our laboratory has demonstrated that
intracerebroventricular administration of LPS leads to
learning and memory deficits [19]. Therefore, the pro-
tective effects of APAP on LPS-induced cognitive defi-
cits were examined in this model. As shown in Fig. 2a,
in the MWM test, the escape latency in all groups im-
proved over time and was significantly shorter during
the third training session than in the first training
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Fig. 2 APAP attenuated behavioural performance after exposure to LPS in mice. a Spatial learning in the MWM on days −3, −2 and −1. Average
escape latency (s) is shown for the three training sessions in the maze. b Swimming speed during probe testing on day 1. c Platform-site crossings
during probe testing on day 1. e Time travelled in the target quadrant during probe testing on day 1. f Percentage of distance travelled in the target
quadrant during probe testing on day 1. d Latency to the platform during spatial working memory testing on days 1, 2 and 3. g–j Representative
trajectories of mice from each experimental group during probe testing in which the hidden platform was removed. The circle represents the previous
location of the platform. Data are expressed as the mean ± SE (n = 20). *P < 0.05, ***P < 0.001 vs. CON group; ##P < 0.01, ###P < 0.001 vs. LPS group;












































Fig. 1 Determine the effect of LPS and APAP on mice in the open field test. The results of spontaneous locomotor activity showing that neither
LPS nor APAP changed the total moving distance (a) or moving duration (b) 24 h after LPS administration. Data are expressed as the mean ± SE
(n = 10). APAP acetaminophen, aCSF artificial cerebrospinal fluid, LPS lipopolysaccharide, SE standard error
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session (P < 0.001), yet no difference was observed be-
tween the groups during the same day, indicating that
all animals were able to learn where the platform was lo-
cated. On day 0, animals underwent microinjection sur-
gery, and on postoperative day 1, mice were subjected to
a probe test for reference memory, during which the
platform was absent. In the probe test, there were no
significant differences in swimming speed between
groups, suggesting again that the poorer performance of
the LPS group was not a result of reduced locomotor
ability (Fig. 2b). It was observed that APAP prevented
memory deficits caused by LPS on postoperative day 1
(FLPS = 14.42, FAPAP = 4.101, FLPS × APAP = 7.754 for
platform-site crossings, P < 0.05; FLPS = 25.43, FAPAP =
4.799, FLPS × APAP = 9.700 for time travelled in the target
quadrant, P < 0.05; FLPS = 50.43, FAPAP = 4.876, FLPS ×APAP
= 17.53 for percentage of distance travelled in the target
quadrant during probe testing, P < 0.05; Fig. 2c, e, f ). On
days 1 to 3, mice were subjected to a working memory
test, during which both the platform and mice were ran-
domly placed in a novel position to assess working- or
trial-dependent learning and memory. If the animal recalls
the sample trial, it will swim a shorter path to the goal
on the second trial. On day 1, it was observed that the
escape latency needed to reached the new platform was
significantly higher (P < 0.05) in the LPS group than in
the CON and APAP group, and there was no significant
difference in escape latency between the A + L group
and the CON and APAP group, although mice in the A
+ L group exhibited a tendency towards an increase in
escape latency (Fig. 2d). On day 2, the escape latency of
the LPS group still showed tendency for a higher la-
tency than that of the other groups, although it did not
reach statistical significance (Fig. 2d). On day 3, the im-
paired performance of the LPS group in the working
memory test returned to control levels, and there was
no significant difference in escape latency among all
groups (Fig. 2d).
Collectively, our results suggest that LPS causes cogni-
tive impairment, specifically a deficit in short-term
memory retention, which can be ameliorated by APAP
treatment.
APAP suppressed the accumulation of pro-inflammatory
cytokines induced by LPS in the mouse hippocampus
We investigated the levels of several pro-inflammatory
cytokines (IL-1β, IL-6 and TNF-α) in the hippocampus,
a brain region where neuroinflammation mainly occurs
in response to brain injury and inflammation [38, 39]. In
accordance with our previous study [19], an ELISA im-
munoassay showed that the level of IL-1β (FLPS = 60.95,
P < 0.001, Fig. 3a), IL-6 (FLPS = 53.98, P < 0.001, Fig. 3b)
and TNF-α (FLPS = 163.6, P < 0.001, Fig. 3c) in the LPS
group was much higher than that in the CON group.
Remarkably, APAP significantly attenuated LPS-induced
increases in IL-1β (FAPAP = 25.65, P < 0.001, Fig. 3a), IL-6
(FAPAP = 11.61, P < 0.001, Fig. 3b) and TNF-α (FAPAP =
37.92, P < 0.001, Fig. 3c) levels. These results suggest that
APAP inhibited LPS-induced accumulation of pro-
inflammatory cytokines in the mouse hippocampus.
APAP prevented microglial activation after
intracerebroventricular administration of LPS
Due to the important role that cytokines and micro-
glial activation play in LPS-induced neuroinflammation
[14, 40–42], we used immunohistochemistry to investi-
gate microglial activation. The immunohistochemistry
results showed that LPS caused obvious microglial activa-
tion in the mouse hippocampal DG regions (FLPS = 109.7,
P < 0.001), CA1 regions (FLPS = 26.93, P < 0.001) and CA3
regions (FLPS = 135.1, P < 0.001) labelled by Iba1 (Fig. 4b).
APAP significantly attenuated LPS-induced microglial
activation (FAPAP = 5.547 and P = 0.0211, FAPAP = 9.321
and P = 0.0042 and FAPAP = 5.098 and P = 0.0301 for DG
regions, CA1 regions and CA3 regions, respectively) in
the hippocampus of mice (Fig. 4b).
a b c
Fig. 3 APAP attenuated the accumulation of pro-inflammatory cytokines induced by LPS in the mouse hippocampus. Levels of IL-1β (a), IL-6 (b)
and TNF-α (c) in samples of the hippocampus 6 h after LPS administration. IL-1β, IL-6 and TNF-α were increased by LPS, and APAP reversed the
accumulation of those pro-inflammation cytokines. Data are expressed as the mean ± SE (n = 5, 6) ***P < 0.001 vs. CON group; ###P < 0.001 vs. LPS
group. APAP acetaminophen, aCSF artificial cerebrospinal fluid, LPS lipopolysaccharide, SE standard error
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APAP increased SOD activity and reduced MDA levels in
the hippocampi of mice after LPS administration
As shown in Fig. 5a, compared to the CON group,
LPS induced a significant decrease in SOD activity in
the hippocampus on postoperative day 1 (FLPS = 24.53,
P < 0.001, n = 6); this abnormal decrease in SOD activity
was largely prevented by APAP (FAPAP = 2.737, P = 0.0111,
n = 6). As demonstrated in Fig. 5b, the MDA level of the
a
b
Fig. 4 APAP attenuated LPS-induced microglial (brown) activation. a Representative images of Iba1-labelled activated microglia in the hippocampi
24 h after LPS administration. a Activated microglia and cell nuclei in the hippocampi on postoperative day 1. b The number of hippocampal
Iba1-positive cells on postoperative day 1 under ×200 magnification. Scale bars: ×100, 200 μm; ×200, 100 μm. Data are expressed as the mean ± SE
(n = 5–6). ***P < 0.001 vs. CON group; #P < 0.05, ##P < 0.01 vs. LPS group. APAP acetaminophen, aCSF artificial cerebrospinal fluid, LPS lipopolysaccharide,
SE standard error
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hippocampi in the LPS group was significantly higher
on postoperative day 1 than that in the CON group
(FLPS = 67.35, P < 0.001, n = 6). Likewise, APAP signifi-
cantly attenuated abnormally increased MDA levels in the
hippocampi of the A + L group (FAPAP = 4.796, P = 0.0099,
n = 6). Meanwhile, no significant difference was found
between the APAP alone and CON groups.
APAP blocked glycogen synthase kinase 3β (GSK3β)
activity and attenuated the BDNF decrease in mice
with LPS-induced hippocampal impairment
GSK3β is an important kinase that was first identified as
the major regulator of glycogen synthase, the key en-
zyme involved in glycogen synthesis. However, similar to
many other kinases, GSK3β was found to regulate nu-
merous other processes, including those involving cell
death, apoptosis and cognitive function [43, 44]. There-
fore, the present experiments were designed to determine
whether APAP is able to modulate GSK3β activity in the
LPS-exposed mouse hippocampus. The total expression
level of GSK3β was not altered by different treatments
(FLPS = 0.17, P > 0.05; FAPAP = 0.01257, P > 0.05; Fig. 6d),
whereas the phospho-GSK3β/GSK3β ratio in the hippo-
campus of LPS-exposed mice was significantly decreased,
and APAP attenuated this reduction (FLPS = 48.37, P <
0.001; FAPAP = 8.867, P = 0.0074; Fig. 6e). These data sug-
gest that APAP treatment downregulates GSK3β activity
by phosphorylating GSK3β in the hippocampus. In the
LPS-treated hippocampus, total GSK3β remained un-
changed, and the activation of GSK3β was relatively
higher than in the CON group.
BDNF can enhance protective pathways and inhibit dam-
aging pathways, supporting the survival of existing neurons
and promoting neurogenesis [45, 46]. The effects of LPS
and APAP on BDNF were evaluated. The expression of
BDNF was reduced in the LPS-treated group, which was
alleviated by APAP (FLPS = 25.73, P < 0.001; FAPAP = 7.706,
P = 0.0117; Fig. 6f), suggesting that APAP may protect hip-
pocampal neurons from LPS-induced damage.
APAP significantly decreased the Bax/Bcl-2 ratio and
neuron apoptosis in the hippocampus of LPS-treated mice
To assess whether the balance of hippocampal pro-
apoptotic protein Bax and anti-apoptotic protein Bcl-2
was affected by LPS, the expression of Bax and Bcl-2
proteins was measured using immunoblotting. As shown
in Fig. 7d, the expression of Bcl-2 protein was signifi-
cantly decreased in the LPS-treated mice (FLPS = 55.54,
P < 0.001, n = 6), whereas APAP treatment was able to
restore Bcl-2 protein content to that comparable to the
CON group (FAPAP = 19.51, P < 0.001, n = 6). The expres-
sion of Bax protein was not different among the four
groups (FLPS = 2.37, FAPAP = 0.062, P > 0.05, Fig. 7e).
Further analysis of the Bax/Bcl-2 ratio, an index of pro-
apoptotic signalling pathway activation [47], demon-
strated that the Bax/Bcl-2 ratio was higher in the LPS
group than in the CON group (FLPS = 27.98, P < 0.001,
n = 6, Fig. 7f ). APAP treatment significantly decreased
the Bax/Bcl-2 ratio in the hippocampi of the A + L group
compared to the LPS group (FAPAP = 6.140, P = 0.0223,
n = 6, Fig. 7f ). In order to observe the effect of APAP
on LPS-induced hippocampal neurons, we carried out
TUNEL assay. We found that the apoptotic cell number
of the DG, CA1 and CA3 regions in the LPS group was
significantly higher than that in the CON group (P < 0.001
for DG regions, P < 0.001 for CA1 regions and P = 0.0013
for CA3 regions, respectively, Fig. 7h). However, APAP sig-
nificantly attenuated LPS-induced neuron apoptosis in the
hippocampal DG, CA1 and CA3 regions (P = 0.0145 for
DG regions, P = 0.0063 for CA1 regions and P = 0.0109 for
CA3 regions, respectively, Fig. 7h). Our results sug-
gested that APAP may ameliorate the learning and













































Fig. 5 APAP increased SOD activity and reduced hippocampal MDA levels after exposure to LPS in mice. a SOD activity in the hippocampus on
postoperative day 1. b The MDA level in the hippocampus on postoperative day 1. Data are expressed as the mean ± SE (n = 6). ***P < 0.001 vs. CON
group; #P < 0.05, ##P < 0.01 vs. LPS group. SOD superoxide dismutase, MDA malondialdehyde, APAP acetaminophen, aCSF artificial cerebrospinal fluid,
LPS lipopolysaccharide, SE standard error
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Discussion
This paper shows that APAP improved cognitive dys-
function induced by cerebroventricular administration of
LPS. The protective effects of APAP on cognitive impair-
ment in mice may be related to its antioxidant and anti-
inflammatory activity, modulating the activity of GSK3β,
as well as its ability to inhibit the mitochondrial perme-
ability transition (MPT) pore and the subsequent apop-
totic pathway.
Recent experimental data suggest that APAP may have
several remarkable effects other than its well-known an-
algesic/antipyretic properties. Thus far, a wide array of
neuroprotective effects of APAP has been reported in
different studies [24, 27–29, 48]. Previous studies have
shown that APAP can protect neurons from degener-
ation in animal models and cell lines of AD [29] and PD
[49] that involves inflammatory and oxidative stress pro-
cesses. Given the evidence that sepsis can cause cogni-
tive impairment in human subjects [50, 51], our study
focused on the effects of APAP in an LPS-induced cog-
nitive impairment mouse model.
The MWM test was chosen as a robust and reliable test
that is strongly correlated with hippocampal-dependent
memory [52, 53]. Escape from water is relatively immune
from activity or body mass differences, making it ideal for
experimental models. As previously reported [19], there
were no significant differences between groups during
the acquisition phase, and 2 μg of LPS (intracerebro-
ventricular administration) caused memory deficits on
postoperative day 1 following the microinjection. In the
preliminary experiment, mice treated with 2 μg of LPS did
not remember where the platform was and searched aim-
lessly instead. We found that 100 mg/kg of APAP amelio-
rated the memory deficits caused by LPS. Similar results
were obtained in formal experiments using the spatial ref-
erence memory test; an obvious inherent memory impair-
ment was observed in the LPS group, and this inherent
memory injury was significantly alleviated by APAP. In
the MWM trail-dependent learning task, an obvious im-
pairment in working memory was observed in the LPS
group, and this working memory injury was alleviated by
APAP although there was no statistical significance. Col-
lectively, our results indicate that LPS causes cognitive im-
pairment, specifically a deficit in short-term memory
retention, which can be ameliorated by APAP treatment.
This finding suggests a potential application of APAP in
patients with or at risk for cognitive impairment. The re-
sults of the current study are consistent with a previous
study that showed that administration of APAP improves
cognitive performance of rodents in the Morris water
maze test [48].
Considerable evidence implicates neuroinflammation
in the pathophysiology of progressive neurodegenerative
disorders such as AD, PD, ALS and MS [5–7]. A link
between increased cytokine formation and neurodegen-
eration has been demonstrated [54]. Thus, we next
evaluated the effect of APAP on neuroinflammatory pro-





Fig. 6 Effect of APAP on the expression of p-GSK3β/GSK3β and BDNF in mice with hippocampal impairment. a–c Protein bands on the gel and
their relative intensities on postoperative day 1. d–f The expression levels of p-GSK3β/GSK3β and BDNF proteins were normalized to that of
β-actin as an internal control. Data are expressed as the mean ± SE (n = 6). ***P < 0.001 vs. CON group; #P < 0.05, ###P < 0.001 vs. LPS group.
APAP acetaminophen, aCSF artificial cerebrospinal fluid, LPS lipopolysaccharide, SE standard error
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resident macrophage in the brain, participates in the co-
ordination of events important for the maintenance of
neuronal health and plays the most important role in
responding to inflammation in the central nervous sys-
tem. Previous studies [32–35, 41] have shown that LPS
triggers microglia activation and consequently induces
pro-inflammatory cytokine secretion within 6 h via the
NF-κB pathway in the mouse hippocampus and that the
nuclear signal of the transcription factor is strongly
reduced or blocked by anti-inflammatory compounds
[55, 56]. In the current study, we demonstrated that in-
tracerebroventricular injection of LPS induced increases
in TNF-α, IL-1β and IL-6 levels in the mouse brain 6 h
after the injection. In addition, microglia labelled by Iba1
in the hippocampus were activated. The current studies
showed that APAP inhibited LPS-induced microglial ac-
tivation and production of pro-inflammatory mediators
including TNF-α, IL-1β and IL-6. Our results are in
accordance with previous reports that APAP blunted
neuronal apoptosis via reduction of the inflammatory
transcription factor NF-κB and reduces inflammatory pro-
tein such as chemokines and cytokines [57]. APAP has the
capability to modulate the release of inflammatory mole-
cules such as PGE2 and IL-6 by Aβ-stimulated astrocytes
[58]. APAP also protects brain endothelial and neuronal
cells against oxidative stress, and menadione-induced in-
crease in chemokines and cytokines was reduced by APAP
[25, 26]. Thus, APAP possesses the ability to block NF-κB
activation and exert a neuroprotective effect, suggesting
that the neuroprotective effects of APAP might be related
to its anti-neuroinflammation effects.
Oxidative stress is defined as an imbalance between
higher cellular levels of reactive oxygen species (ROS),
e.g. superoxide and hydroxyl radicals [59], and cellular
antioxidant defence [60]. If ROS are not controlled by
enzymatic and non-enzymatic antioxidants, they can
cause oxidative injury, i.e. peroxidation of cell membrane
phospholipids, proteins (receptors and enzymes) and
DNA. The brain is extremely susceptible to oxidative
damage induced by ROS because it generates very high
levels of ROS due to its very high aerobic metabolism
and blood perfusion and its relatively poor enzymatic
antioxidant defence [61]. The brain contains polyunsat-
urated fatty acids (PUFAs), which can readily be peroxi-
dized [62]. Lipid peroxidation (LP) causes injury to cells
and intracellular membranes and may lead to cell de-
struction and subsequently cell death [59, 63]. Therefore,
oxidative stress participates in neuronal injury and cog-
nitive impairment. However, increasing evidence
suggests that APAP has unappreciated antioxidant prop-
erties. For example, APAP can protect dopaminergic
neurons from 1-methyl-4-phenylpyridinium (MPP+)-in-
duced toxicity in mitochondria by scavenging ROS [23].
Additionally, administration of APAP to rats significantly
attenuates quinolinic acid-induced superoxide gener-
ation [24]. APAP has been shown to be a potent scaven-
ger of ROS [26]. Previous studies have indicated that
after intracerebroventricular injection of LPS, significant
changes in oxidative stress markers were found in the
hippocampus of mice [19]. Indeed, decreased activity of
SOD and increased levels of MDA were found after LPS
microinjection in the hippocampi of animals in the LPS
group. Abnormal changes in the activity of SOD and the
levels of MDA were partially reversed by APAP, suggest-
ing that the neuroprotective effects of APAP might be
related to its antioxidant effects.
GSK3β regulates many crucial cellular processes in the
brain and plays an important role in the inflammatory
process [64, 65]. GSK-3β overexpression induces apoptosis
and causes a reduction in postsynaptic density number
and volume in hippocampal granule neurons [66], a
phenomenon that may be related to cognitive impairment.
GSK3β is constitutively active in the cytoplasm, but its ac-
tivity can be inhibited by phosphorylation of protein kin-
ase B (Akt) at the site of serine 9 [67]. Our results have
shown that intracerebroventricular LPS depressed the
phospho-GSK3β/GSK3β ratio in the hippocampus, and
dysregulation of this signal transduction pathway could re-
sult in failure to adequately repress GSK-3β, thus allowing
GSK-3β to remain abnormally active. This status has been
proven to contribute to various pathologies, including
neurodegenerative and cognitive disorders, which is in
line with behavioural performance [65, 68]. However,
APAP attenuated the reduction by phosphorylating
GSK3β in the hippocampus and blocked GSK-3β activ-
ity in response to LPS, thus providing protection from
LPS-induced apoptosis and cognitive impairment. This
observation might be caused by the antioxidant effects
of APAP. It is known that oxidative stress can activate
GSK3β by Src- and calcium-dependent mechanisms
(See figure on previous page.)
Fig. 7 Effect of APAP on the expression of Bax/Bcl-2 and neuron apoptosis in mice with hippocampal impairment. a–c Protein bands on the gel
and their relative intensities on postoperative day 1. d–f The expression levels of Bax/Bcl-2 proteins were normalized to that of β-actin as an
internal control. g CA1, CA3 and DG regions of hippocampal from indicated group of mice. TUNEL staining demonstrated neuron apoptosis
on postoperative day 1. h The number of hippocampal apoptotic neurons on postoperative day 1 under ×400 magnification. Scale bars: ×100,
200 μm; ×400, 50 μm. Data are expressed as the mean ± SE (n = 6). **P < 0.01, ***P < 0.001 vs. CON group; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. LPS
group. APAP acetaminophen, aCSF artificial cerebrospinal fluid, LPS lipopolysaccharide, SE standard error
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[69]. However, recent studies have shown that APAP
could modulate microsomal pores, rectify Ca2+ homeo-
stasis and, therefore, decrease ROS production in the
rat hippocampus [70].
BDNF and its signalling pathways are firmly implicated
in neuronal differentiation and survival. Numerous pieces
of evidence indicate that BDNF regulates both early and
late phases of long-term potentiation in the hippocampus
[71]. Its regulation of synaptic plasticity may underlie
hippocampus-dependent learning and memory. Most
studies [17, 72–74], including ours, agreed that LPS injec-
tions extensively reduced the expression of BDNF in the
brain. This decline was altered by APAP treatment in our
study. The underlying mechanism for this effect might be
that the active GSK3β, caused by LPS injection, phos-
phorylates the cyclic adenosine monophosphate (cAMP)
response element-binding protein (CREB) and could
thereby regulate transcription of genes related to synaptic
plasticity and neurogenesis, including BDNF [75]. As our
results showed, APAP blocked GSK-3β activity in mice
with LPS-induced hippocampal impairment. Therefore,
the decrease in BDNF was subsequently reversed.
It is well known that LPS causes cognitive lesions and
that this process involves apoptosis [76, 77]. A large
number of proteins operate in concert to regulate apop-
tosis. Bcl-2 is of particular interest as it has been re-
ported to be protective against oxidative stress, reducing
cell death induced by reactive oxygen species [78–80].
Previous studies have shown that cells overexpressing
anti-apoptotic Bcl-2 exhibit a marked reduction in apop-
tosis, which suggests that anti-apoptotic Bcl-2 could
independently affect the rate of apoptosis [81]. Anti-
apoptotic Bcl-2 family members can attenuate the re-
lease of killer proteins, influence mitochondrial integrity
and prevent apoptosis [82, 83]. Similar studies employ-
ing neuronal cells modelling protein aggregation typical
of Alzheimer’s disease have also reported a significant
reduction in apoptotic cell death when these cells over-
expressed anti-apoptotic Bcl-2 [84]. Recent in vitro data
have shown that APAP increases expression of anti-
apoptotic protein Bcl-2 in brain endothelial cells and
neuronal cells experiencing oxidative stress as a by-
product of inflammation [25, 26]. In this paper, our re-
sults are consistent with previous studies; we found that
LPS-induced cognitive impairment was associated with
decreased Bcl-2 expression and an elevated Bax/Bcl-2
ratio and that APAP protects against apoptosis, thereby
assuaging cognitive impairment, by increasing the ex-
pression of anti-apoptotic Bcl-2 proteins and decreasing
the hippocampal neuron apoptosis. APAP is likely to
prevent mitochondrial pore dysfunction, resulting in the
stabilization of pro-apoptotic proteins and consequently
minimizing their deleterious effects on MPT, which pre-
cede apoptosis and necrosis [83].
Conclusions
In summary, obvious cognitive impairment was shown
in mice that underwent intracerebroventricular micro-
injection of LPS. Our in vivo studies showed that APAP
could alleviate cognitive impairment induced by LPS. Its
protective mechanism may be related to its antioxidant
and anti-inflammatory properties and modulation of
GSK3β activity, as well as its ability to inhibit the MPT
pore and subsequent apoptotic pathway. Although the
molecular mechanisms of action of APAP are controver-
sial due to its hepatotoxicity at high doses [85], further in-
vestigation of the neuroprotective activity of APAP in the
mammalian system is warranted given the prospect for
this common medication to be used for prophylactic, as
well as adjuvant, therapy for neurodegenerative diseases
resulting from oxidative and inflammatory damage.
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